Dermata Therapeutics, Inc.
Research - San Diego, California, United States
Dermata Therapeutics, Inc. Employees
Dermata Therapeutics, Inc. Senior Management
Dermata Therapeutics, Inc. Details
Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Dermata Therapeutics, Inc. Technologies
Email Providers
Outlook
Load Balancers
Apache
Fonts
Typekit
Other
Mobile Friendly